Your browser doesn't support javascript.
loading
Effects of Comorbidities on Outcomes of Patients With Intraductal Papillary Mucinous Neoplasms.
Sahora, Klaus; Ferrone, Cristina R; Brugge, William R; Morales-Oyarvide, Vicente; Warshaw, Andrew L; Lillemoe, Keith D; Fernández-del Castillo, Carlos.
Afiliação
  • Sahora K; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Ferrone CR; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Brugge WR; Department of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Morales-Oyarvide V; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Warshaw AL; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Lillemoe KD; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Fernández-del Castillo C; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: CFERNANDEZ@mgh.harvard.edu.
Clin Gastroenterol Hepatol ; 13(10): 1816-23, 2015 Oct.
Article em En | MEDLINE | ID: mdl-25956837
ABSTRACT
BACKGROUND &

AIMS:

Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas occur mostly in older individuals. Individual life expectancy and risk of death from other factors must be carefully considered in analyzing the risks that IPMNs pose. We investigated whether there is a subset of patients with IPMNs and a high risk of dying from other causes who would not benefit from pancreatic surgery.

METHODS:

We collected data from 725 patients at Massachusetts General Hospital who underwent resection or have been under observation for IPMNs from 1992 through 2012. Comorbidities were classified according to the age-adjusted Charlson comorbidity index (CACI). Causes of death were recorded, and survival data were analyzed by the Kaplan-Meier method.

RESULTS:

The patients' median CACI score was 3; 10% of patients had CACI of 7 or more. Of the entire cohort, 55% underwent resection, and the remaining 45% have been under observation. After a median follow-up period of 5 years, 177 patients died (24%, 55% of deaths within 5 years of diagnosis); 78% of deaths were not related to IPMNs. The median survival time for all patients with CACI score of 7 or more was 43 months. Multivariate regression analysis revealed that the chance of non-IPMN-related death within 3 years of diagnosis is 11-fold higher for patients with CACI score of 7 or more than for patients with lower scores.

CONCLUSIONS:

The CACI can be used to identify patients with a high risk of death from factors other than IPMNs within a few years after diagnosis. These patients are therefore not likely to benefit from further IPMN observation or pancreatic resection.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Papilar / Adenocarcinoma Mucinoso / Carcinoma Ductal Pancreático Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Clin Gastroenterol Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Papilar / Adenocarcinoma Mucinoso / Carcinoma Ductal Pancreático Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Clin Gastroenterol Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2015 Tipo de documento: Article